Werewolf Therapeutics Stock Price, News & Analysis (NASDAQ:HOWL) $2.90 -0.02 (-0.68%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$2.85▼$2.9650-Day Range$1.78▼$3.1752-Week Range$1.55▼$4.57Volume33,597 shsAverage Volume138,213 shsMarket Capitalization$104.95 millionP/E RatioN/ADividend YieldN/APrice Target$10.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Werewolf Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside264.7% Upside$10.58 Price TargetShort InterestHealthy2.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.05Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.03) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.32 out of 5 starsMedical Sector238th out of 954 stocksPharmaceutical Preparations Industry60th out of 362 stocks 3.5 Analyst's Opinion Consensus RatingWerewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.58, Werewolf Therapeutics has a forecasted upside of 264.7% from its current price of $2.90.Amount of Analyst CoverageWerewolf Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.30% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 62.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOWL. Previous Next 2.8 News and Social Media Coverage News SentimentWerewolf Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for HOWL on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.44% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.03) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Werewolf Therapeutics Stock (NASDAQ:HOWL)Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Read More HOWL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOWL Stock News HeadlinesDecember 7, 2023 | finance.yahoo.comInstitutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$14m last week but private equity firms profited the mostDecember 4, 2023 | realmoney.thestreet.comWolfspeed Could Rally in the Next Few Weeks: Should You Join the Pack?December 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 22, 2023 | finance.yahoo.comWerewolf Therapeutics to Present at the Evercore ISI HealthCONx ConferenceNovember 17, 2023 | msn.comFolklore strategy game Howl is a turn-based puzzle for perfectionistsNovember 14, 2023 | finance.yahoo.comWerewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 3, 2023 | msn.comWhy Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?November 3, 2023 | marketwatch.comWerewolf Therapeutics Shares Jump on Encouraging Trial DataDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 3, 2023 | benzinga.comWerewolf Therapeutics' Cancer Drug Shows Promise in Early Study for Solid Tumors, Stock SoarsNovember 3, 2023 | msn.comWerewolf Therapeutics jumps on early-sage data from lead programNovember 3, 2023 | finance.yahoo.comWerewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNovember 1, 2023 | markets.businessinsider.comPromising Phase 1 Results and Improved Therapeutic Index Drive ‘Buy’ Rating for Werewolf TherapeuticsNovember 1, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Werewolf Therapeutics (HOWL), Ascendis Pharma (ASND)October 31, 2023 | finance.yahoo.comWerewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 30, 2023 | finance.yahoo.comThis Just In: Analysts Are Boosting Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Outlook for This YearSeptember 28, 2023 | yahoo.comThe Best Werewolf Movies of All Time, from ‘Ginger Snaps’ to ‘Teen Wolf’ to ‘An American Werewolf in London’September 27, 2023 | finance.yahoo.comWerewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 14, 2023 | msn.com'Lazy' Wolfdog Pretending to Howl for the Camera Has Internet in StitchesSeptember 11, 2023 | finance.yahoo.comWerewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124September 5, 2023 | finance.yahoo.comWerewolf Therapeutics to Participate in Upcoming Investor ConferencesAugust 25, 2023 | msn.comWedbush Initiates Coverage of Werewolf Therapeutics (HOWL) with Outperform RecommendationAugust 24, 2023 | msn.comWerewolf gains as Wedbush cites bullish views ahead of key readoutAugust 24, 2023 | theglobeandmail.comBiotech Soars On New Price Target And Analyst RatingAugust 24, 2023 | markets.businessinsider.comSmall Cancer Player Werewolf Therapeutics' Stock Undervalued: Analyst Says Treatment Platform UnderappreciatedAugust 13, 2023 | finance.yahoo.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?August 11, 2023 | finance.yahoo.comWerewolf Therapeutics Second Quarter 2023 Earnings: Beats ExpectationsSee More Headlines Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HOWL CUSIPN/A CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Target$10.58 High Stock Price Target$15.00 Low Stock Price Target$8.30 Potential Upside/Downside+264.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,810,000.00 Net Margins-144.98% Pretax Margin-144.98% Return on Equity-31.44% Return on Assets-20.81% Debt Debt-to-Equity Ratio0.33 Current Ratio9.64 Quick Ratio9.64 Sales & Book Value Annual Sales$25.73 million Price / Sales4.08 Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book0.73Miscellaneous Outstanding Shares36,192,000Free Float26,746,000Market Cap$104.96 million OptionableNot Optionable Beta0.18 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Daniel J. Hicklin Ph.D. (Age 59)Founder, CEO, President, Secretary & Director Comp: $817.31kDr. Cynthia Seidel-Dugan Ph.D. (Age 64)Chief Scientific Officer Comp: $600.35kDr. Randi Isaacs M.D. (Age 67)Chief Medical Officer Comp: $637.15kMr. Timothy W. Trost CPA (Age 65)CFO, Treasurer & Assistant Secretary Comp: $511.88kDr. Chulani Karunatilake Ph.D. (Age 64)Chief Technology Officer Comp: $343.43kMs. Ellen A. Lubman M.B.A. (Age 47)Chief Business Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRRallybioNASDAQ:RLYBImmix BiopharmaNASDAQ:IMMXLongboard PharmaceuticalsNASDAQ:LBPHG1 TherapeuticsNASDAQ:GTHXView All CompetitorsInsiders & InstitutionsSchonfeld Strategic Advisors LLCSold 151,978 shares on 11/14/2023Ownership: 0.490%Simplex Trading LLCSold 100 shares on 11/1/2023Ownership: 0.000%Ra Capital Management, L.P.Bought 1,853,000 shares on 1/6/2023Total: $4.10 M ($2.21/share)View All Insider TransactionsView All Institutional Transactions HOWL Stock Analysis - Frequently Asked Questions Should I buy or sell Werewolf Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOWL shares. View HOWL analyst ratings or view top-rated stocks. What is Werewolf Therapeutics' stock price target for 2024? 3 brokerages have issued 1-year price targets for Werewolf Therapeutics' stock. Their HOWL share price targets range from $8.30 to $15.00. On average, they anticipate the company's share price to reach $10.58 in the next year. This suggests a possible upside of 264.7% from the stock's current price. View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts. How have HOWL shares performed in 2023? Werewolf Therapeutics' stock was trading at $2.05 at the start of the year. Since then, HOWL shares have increased by 41.5% and is now trading at $2.90. View the best growth stocks for 2023 here. Are investors shorting Werewolf Therapeutics? Werewolf Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 518,500 shares, an increase of 62.8% from the October 31st total of 318,400 shares. Based on an average daily volume of 827,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.3% of the shares of the company are short sold. View Werewolf Therapeutics' Short Interest. When is Werewolf Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our HOWL earnings forecast. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.04. The firm had revenue of $5.90 million for the quarter, compared to analyst estimates of $15.60 million. Werewolf Therapeutics had a negative net margin of 144.98% and a negative trailing twelve-month return on equity of 31.44%. When did Werewolf Therapeutics IPO? (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Werewolf Therapeutics' major shareholders? Werewolf Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Schonfeld Strategic Advisors LLC (0.49%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard. View institutional ownership trends. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:HOWL) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.